Ligand id: 9250

Name: erenumab

No information available.
Summary of Clinical Use
Erenumab received US FDA approval in May 2018 as a once-monthly injection as a preventative treament for migraine sufferers. One of the determining clinical trials leading to this marketing authorisation was the Phase 3 ARISE trial, NCT02483585, for which results were published in May 2018 [2]. Phase 2 trial results were published in [8] and reported a significant reduction in migraine episodes in the patient group receiving the highest erenumab dose (70mg; monthly subcutaneous administration) compared to the placebo control group. EMA approval was granted in August 2018 for the treament of patients who suffer 4 or more mirgaines/month.
Mechanism Of Action and Pharmacodynamic Effects
Calcitonin gene-related peptide (CGRP) is a neuropeptide involved in migraine pathophysiology [3-5]. Antagonism of CGRP's interaction with its cognate receptor CGRPR by small molecules proved that this was a valid pathway for migraine intervention. However, small molecule CGRPR antagonists showed considerable hepatotoxicity which precluded futher clinical development. More recently, anti-CGRPR antibodies with antagonist activity have entered clinical development pipelines as an alternative to small molecule antagonists. Erenumab is one such monoclonal.
Anti-CGRP ligand antibodies are also in development to target this same migraine pathway (for example, galcanezumab, fremanezumab and ALD403) [6].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02483585 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention Phase 3 Interventional Amgen
External links